Ipilimumab (Yervoy) has been approved by the FDA for the treatment of patients aged greater than or equal to 12 years with unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.
Publications
Melanoma Journal Articles for June 2017
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy?
FDA grants orphan drug designation to pIL-12 for unresectable melanoma
The FDA granted orphan drug designation to tavokinogene telsaplasmid for the treatment of unresectable metastatic melanoma, according to the agent’s manufacturer.
Study: Common surgical treatment for melanoma does not improve patients’ overall survival
Patients who receive the standard surgical treatment for melanoma that has spread to one or more key lymph nodes do not live longer, a major new study shows.